Supriya Lifescience

Supriya Lifescience Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of Supriya Lifescience (SUPRIYA.NS) as of Oct 16, 2026 is -1.71. In the previous year, Net Debt to Free Cash Flow Ratio was -7.24 — a change of -76.41% (higher).

Net Debt/FCF

-1.71

YoY

-76.41%

Last updated:

Net Debt to Free Cash Flow Ratio of Supriya Lifescience is 2026 -1.71 . Net Debt to Free Cash Flow Ratio of Supriya Lifescience was 2025 -7.24 . It decreases by -76.41% higher compared to the previous year.

The Supriya Lifescience Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2019
1.92 INR
Jan 1, 2020
0.11 INR
Jan 1, 2021
-0.45 INR
Jan 1, 2022
17.79 INR
Jan 1, 2023
3.20 INR
Jan 1, 2024
2.15 INR
Jan 1, 2025
-7.24 INR
Jan 1, 2026
-1.71 INR
The Supriya Lifescience Net Debt/FCF history
YEARNet Debt/FCFYoY
-1.71-76.41%
-7.24-437.16%
2.15-32.91%
3.20-82.01%
17.79-4,060.70%
-0.45-518.88%
0.11-94.41%
1.92-80.29%
9.72—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Supriya Lifescience Stock analysis

What does Supriya Lifescience do? Supriya Lifescience Ltd is a pharmaceutical company based in Mumbai, India, operating within the healthcare sector. The company specializes in the research, development, and manufacturing of active pharmaceutical ingredients (APIs), with a focus on niche therapeutic segments. It employs 392 full-time staff and completed its initial public offering (IPO) on December 28, 2021. The firm's manufacturing facilities are located in Maharashtra, and it exports products to approximately 86 countries. Its product portfolio includes APIs for antihistamines, anesthetics, anti-asthma treatments, and other therapeutic areas such as analgesics and vitamins. Specific products mentioned include Chlorphenamine Maleate, Pheniramine Maleate, Brompheniramine Maleate, Dexchlorpheniramine Maleate, Mepyramine / Pyrilamine Maleate, Dexbrompheniramine Maleate, Cetirizine DiHCL, Diphenhydramine HCL, Bisoprolol Fumarate, Nicorandil, Mecobalamin, Hydroxocobalamin Sulphate, Hydroxocobalamin Acetate, and Hydroxocobalamin Hydrochloride. The company is engaged in the production of bulk drugs and pharmaceutical chemicals, serving global markets through its export activities. It operates with a focus on niche API products, addressing specific therapeutic needs across multiple categories. The company's website is https://supriyalifescience.com/. Supriya Lifescience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Supriya Lifescience stock

Net Debt to Free Cash Flow Ratio of Supriya Lifescience is -1.71 in 2026.

Net Debt to Free Cash Flow Ratio of Supriya Lifescience changed from -7.24 to -1.71, representing a -76.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Supriya Lifescience since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Supriya Lifescience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Supriya Lifescience

All Key Metrics — Supriya Lifescience